Tumourigenicity and radiation resistance of mesenchymal stem cells

References

• Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756–60.
   PubMed Web of Science ®Google Scholar
• Phillips TM, McBride WH, Pajonk F. The response of CD24-/low/CD44 + breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006;98:1777–85.
   PubMed Web of Science ®Google Scholar
• Rich JN. Cancer stem cells in radiation resistance. Cancer Res 2007;67:8980.
   PubMed Web of Science ®Google Scholar
• Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, . A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004;101:14228–33.
   PubMed Web of Science ®Google Scholar
• Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275–84.
   PubMed Web of Science ®Google Scholar
• Serakinci N, Guldberg P, Burns JS, Abdallah B, Schrodder H, Jensen T, . Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene 2004;23:5095–8.
   PubMed Web of Science ®Google Scholar
• Simonsen JL, Rosada C, Serakinci N, Justesen J, Stenderup K, Rattan SI, . Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol 2002;20:592–6.
   PubMed Web of Science ®Google Scholar
• D'Andrea FP, Safwat A, Kassem M, Gautier L, Overgaard J, Horsman MR. Cancer stem cell overexpression of nicotinamide N-methyltransferase enhances cellular radiation resistance. Radiother Oncol 2011;99:373–8.
   PubMed Web of Science ®Google Scholar
• Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, . Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci 2003;100:15178–83.
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci 2003;100:3983–8.
   PubMed Web of Science ®Google Scholar
• Strauss R, Li Z-Y, Liu Y, Beyer I, Persson J, Sova P, . Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS ONE 2011;6.
   Google Scholar
• El-Guendy N, Zhao Y, Gurumurthy S, Burikhanov R, Rangnekar VM. Identification of a unique core domain of Par-4 sufficient for selective apoptosis induction in cancer cells. Mol Cell Biol 2003;23:5516–25.
   PubMedGoogle Scholar
• Montuori N, Carriero MV, Salzano S, Rossi G, Ragno P. The cleavage of the urokinase receptor regulates its multiple functions. J Biol Chem 2002;277:46932–9.
   PubMed Web of Science ®Google Scholar
• Gondi CS, Kandhukuri N, Dinh DH, Gujrati M, Rao JS. Downregulation of uPAR and uPA activates caspase mediated apoptosis, inhibits the PI3k/AKT pathway. Int J Oncol 2007;31:19.
   PubMedGoogle Scholar
• Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: Recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003;22:205–22.
   PubMed Web of Science ®Google Scholar
• Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463.
   PubMed Web of Science ®Google Scholar
• Hotary KB, Allen ED, Brooks PC, Datta NS, Long MW, Weiss SJ. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003;114:33–45.
   PubMed Web of Science ®Google Scholar
• Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005;120:303–13.
   PubMed Web of Science ®Google Scholar
• Sun T, Gao Y, Tan W, Ma S, Zhang X, Wang Y, . Haplotypes in matrix metalloproteinase gene cluster on chromosome 11q22 contribute to the risk of lung cancer development and progression. Clin Cancer Res 2006;12:7009–17.
   PubMedGoogle Scholar
• Bouez C, Reynaud C, Noblesse E, Thépot A, Gleyzal C, Kanitakis J, . The Lysyl oxidase LOX is absent in basal and squamous cell carcinomas and its knockdown induces an invading phenotype in a skin equivalent model. Clin Cancer Res 2006;12:1463–9.
   PubMedGoogle Scholar
• Villadangos JA. Presentation of antigens by MHC class II molecules: Getting the most out of them. Mol Immunol 2001;38:329–46.
   PubMedGoogle Scholar
• Glew SS, Duggan-Keen M, Cabrera T, Stern PL. HLA class II antigen expression in human papillomavirus-associated cervical cancer. Cancer Res 1992;52:4009–16.
   PubMed Web of Science ®Google Scholar
• El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, . WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817–25.
   PubMed Web of Science ®Google Scholar
• Wajant H. The Fas signaling pathway: More than a paradigm. Science 2002;296:1635–6.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Li M, Wang H, Agrawal S, Zhang R. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci 2003;100:11636–41.
   PubMed Web of Science ®Google Scholar
• Tomasini R, Seux M, Nowak J, Bontemps C, Carrier A, Dagorn JC, . TP53INP1 is a novel p73 target gene that induces cell cycle arrest and cell death by modulating p73 transcriptional activity. Oncogene 2005;24:8093–104.
   PubMedGoogle Scholar
• Wu GS, Burns TF, McDonald ER 3rd, Jiang W, Meng R, Krantz ID, . KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997;17:141.
   PubMed Web of Science ®Google Scholar
• Bauskin AR, Brown DA, Kuffner T, Johnen H, Luo XW, Hunter M, . Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res 2006;66:4983–6.
   PubMed Web of Science ®Google Scholar
• Maeda S, Nobukuni T, Shimo-Onoda K, Hayashi K, Yone K, Komiya S, . Sortilin is upregulated during osteoblastic differentiation of mesenchymal stem cells and promotes extracellular matrix mineralization. J Cell Physiol 2002;193:73–9.
   PubMedGoogle Scholar